BACKGROUND: To determine the relationship between markers of innate immunity and clinical outcomes in patients with heart failure (HF) after acute myocardial infarction (AMI). Atherogenesis and HF is associated with the altered control of inflammation by innate immune defenses that include pattern-recognition molecules such as Toll-like receptors (TLRs) and mannose-binding lectin (MBL). METHODS AND RESULTS: We assessed circulating levels, and relationships with adverse outcomes of MBL and sTLR2 levels in 234 patients with AMI complicated with HF. Blood was sampled at baseline (median 3 days after AMI), 1 month, 1 year, and 2 years. For comparison, we also measured MBL and sTLR2 levels in 20 age- and sex-matched healthy controls. Patients with post-MI HF had markedly decreased serum levels of sTLR2 at baseline that increased during follow-up, but did not reach the concentrations present in healthy controls. In contrast, serum MBL levels were initially normal in patients with post-MI HF, but decreased during follow-up, and MBL levels measured 1 month after the index infarct were inversely associated with a higher incidence of reinfarction. CONCLUSION: These findings suggest that circulating levels of MBL and sTLR2 may reflect different aspects of the innate immune response and further suggest the involvement of innate immunity responses in the pathogenesis of post-MI HF.
BACKGROUND: To determine the relationship between markers of innate immunity and clinical outcomes in patients with heart failure (HF) after acute myocardial infarction (AMI). Atherogenesis and HF is associated with the altered control of inflammation by innate immune defenses that include pattern-recognition molecules such as Toll-like receptors (TLRs) and mannose-binding lectin (MBL). METHODS AND RESULTS: We assessed circulating levels, and relationships with adverse outcomes of MBL and sTLR2 levels in 234 patients with AMI complicated with HF. Blood was sampled at baseline (median 3 days after AMI), 1 month, 1 year, and 2 years. For comparison, we also measured MBL and sTLR2 levels in 20 age- and sex-matched healthy controls. Patients with post-MI HF had markedly decreased serum levels of sTLR2 at baseline that increased during follow-up, but did not reach the concentrations present in healthy controls. In contrast, serum MBL levels were initially normal in patients with post-MI HF, but decreased during follow-up, and MBL levels measured 1 month after the index infarct were inversely associated with a higher incidence of reinfarction. CONCLUSION: These findings suggest that circulating levels of MBL and sTLR2 may reflect different aspects of the innate immune response and further suggest the involvement of innate immunity responses in the pathogenesis of post-MI HF.
Authors: Ming Zhang; Yunfang Joan Hou; Erdal Cavusoglu; Daniel C Lee; Rudi Steffensen; Liming Yang; Daniel Bashari; Jose Villamil; Motaz Moussa; George Fernaine; Jens C Jensenius; Jonathan D Marmur; Wilson Ko; Ketan Shevde Journal: Int J Cardiol Date: 2011-12-15 Impact factor: 4.164
Authors: Stephane Heymans; Emilio Hirsch; Stefan D Anker; Pal Aukrust; Jean-Luc Balligand; Jan W Cohen-Tervaert; Helmut Drexler; Gerasimos Filippatos; Stephan B Felix; Lars Gullestad; Denise Hilfiker-Kleiner; Stefan Janssens; Roberto Latini; Gitte Neubauer; Walter J Paulus; Burkert Pieske; Piotr Ponikowski; Blanche Schroen; Heinz-Peter Schultheiss; Carsten Tschöpe; Marc Van Bilsen; Faiez Zannad; John McMurray; Ajay M Shah Journal: Eur J Heart Fail Date: 2009-02 Impact factor: 15.534
Authors: Bethany M Henrick; Xiao-Dan Yao; Ameer Y Taha; J Bruce German; Kenneth Lee Rosenthal Journal: Front Immunol Date: 2016-08-02 Impact factor: 7.561
Authors: Patricia Langjahr; David Díaz-Jiménez; Marjorie De la Fuente; Estefhany Rubio; Douglas Golenbock; Francisca C Bronfman; Rodrigo Quera; María-Julieta González; Marcela A Hermoso Journal: PLoS One Date: 2014-12-22 Impact factor: 3.240